

#4
Rec'd PCT/PTO 19 SEP 2005

10/518496

PATENT

Customer No. 22,852

Attorney Docket No. 09757.0007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Maria PRAT QUINONES et al.

Application No.: 10/518,496

Filing Date: December 20, 2004

For: Novel Quinuclidine Derivatives and Medicinal
Compositions Containing the Same

)
)
) Group Art Unit: Unassigned
)
) Examiner: Unassigned
)
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Box: PCT

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application

Copies of the listed foreign and non-patent literature documents are attached.

An English translation of the abstract of the non-English document is enclosed.

The following applies to the attached non-English document:

FR 2 012 964—Applicant is listing U.S. Patent No. 3,714,357 in the attached form PTO /SB/08, which is believed to be related to FR 2 012 964.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. WO93/16048;
2. JP9-328469; and
3. WO02/00652.

An English-language abstract of the documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 19, 2005

By

A handwritten signature in black ink, appearing to read "Anthony C. Tridico", is written over a horizontal line.

Anthony C. Tridico

Reg. No. 45,958

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/518,496
				Filing Date	December 20, 2004
				First Named Inventor	Maria PRAT QUINONES
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	09757.0007

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-3,714,357	01/30/1973	Gueremy et al.	

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		CA 2,155,320	08/19/1993	Fujisawa Pharmaceutical Co., Ltd.		
		EP 0 424 021 A1	4/24/1991	Pfizer Ltd.		
		EP 0 747 355 A1	12/11/1996	Yamanouchi Pharmaceutical Co., Ltd.		
		EP 0 801 067 A1	10/15/1997	Yamanouchi Pharmaceutical Co., Ltd.		
		EP 0 863 141 A1	09/09/1998	Banyu Pharmaceutical Co., Ltd.		
		EP 0 930 298 A1	07/21/1999	Banyu Pharmaceutical Co., Ltd.		
		FR 2 012 964	03/27/1970	Societe Generale de Recherches & D'Applications Scientifiques		
		JP 09-328469	12/22/1997	Fujisawa Pharmaceutical Co., Ltd.		Abstract
		WO01/04118 A2	01/18/2001	Almirall Prodesfarma SA		
		WO02/053564 A2	07/11/2002	Almirall Prodesfarma AG		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		N.N. Godovikov, et al., "Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides", Khim. Farm. Zh., Vol. 19, No. 9, pp 1060-1061, 1985.	Abstract
		J. Lars et al., "Some quinuclidine derivatives with potential antimalarial activity", Acta Pharm. Suecica", Vol. 5, pp. 71-76, 1968.	
		L. Noronha-Blob et al., "Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate", European Journal of Pharmacology, Vol. 221, pp. 97-103, 1992.	
		S.H. Gao et al., "Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit", Chemical Journal of Chinese Universities, Vol. 20, No. 2, pp. 232-236, 1999.	Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.